Get the weekly longevity research breakdown → Join free
DNA and aging research laboratory for David Sinclair longevity protocol
Longevity & Optimization

David Sinclair’s Longevity Protocol 2026: NMN, Resveratrol, and the Aging Debate

By Mike Hartnett
March 1, 2026 22 Min Read
9 0

Affiliate Disclosure: CoreStacks may earn a commission through affiliate links in this article. This never influences which supplements we report on or how we present expert recommendations. We report what Dr. Sinclair has publicly shared about his own protocol across podcasts, published research, and his book Lifespan.

Table Of Content

What Supplements Does David Sinclair Take in 2026?

David Sinclair, Harvard Medical School professor of genetics and author of Lifespan: Why We Age — and Why We Don’t Have To, has publicly shared one of the most aggressive anti-aging supplement and pharmaceutical regimens of any prominent longevity researcher. His daily protocol centers on NMN (1g), resveratrol (1g mixed with yogurt), metformin (1,700mg total), vitamin D3, omega-3 fatty acids, quercetin, spermidine, and fisetin. He combines this with intermittent fasting, regular exercise, and cold exposure. Sinclair’s approach is rooted in his Information Theory of Aging — the idea that aging is driven primarily by epigenetic noise, and that it can be slowed or even partially reversed.

Important: This article reports what Dr. Sinclair has publicly shared about his own supplement use and research. We are not recommending these supplements or dosages. Consult a physician before making changes to your health regimen.

David Sinclair’s Complete Supplement & Intervention Stack 2026

This table summarizes every supplement and pharmaceutical intervention Sinclair has publicly discussed as part of his personal protocol, compiled from his appearances on Joe Rogan Experience, his book Lifespan, published interviews, social media posts, and his Harvard lab’s research output.

Supplement / Intervention Purpose (As Stated by Sinclair) Reported Dose Timing Key Source
NMN (Nicotinamide Mononucleotide) Boost NAD+ levels, support sirtuin activation, cellular energy 1g/day Morning, mixed with yogurt Lifespan (2019), JRE #1670, multiple interviews
Resveratrol Activate sirtuins (especially SIRT1), antioxidant 1g/day Morning, mixed with yogurt (fat-soluble) Lifespan (2019), JRE #1670, Harvard lectures
Metformin Activate AMPK, mimic caloric restriction, longevity 850mg morning + 850mg evening Morning and evening Lifespan (2019), JRE #1670, TAME trial advocacy
Vitamin D3 Immune function, bone health, general health Not publicly specified Daily Interviews, social media
Omega-3 (EPA/DHA) Cardiovascular health, anti-inflammatory Not publicly specified Daily Interviews
Quercetin Senolytic activity, anti-inflammatory Not publicly specified Daily Interviews, social media
Spermidine Autophagy activation, cellular renewal Not publicly specified Daily Interviews, conference talks
Fisetin Senolytic, clearing senescent cells Not publicly specified Periodically Interviews, social media
Statin + PCSK9 Inhibitor Cholesterol management Prescription As prescribed Mentioned in interviews
Intermittent Fasting Activate sirtuins, AMPK, autophagy Skips breakfast, sometimes lunch Daily Lifespan (2019), JRE appearances
Regular Exercise Cardiovascular health, NAD+ preservation Varied (running, walking, weights) Multiple times/week Interviews, social media
Cold Exposure Metabolic activation, brown fat stimulation Varied Periodically Interviews

Check current pricing on Amazon

Get the latest longevity research in your inbox every week.

Join Free →

Detailed Breakdown: Sinclair’s Core Supplements and Interventions

1. NMN (Nicotinamide Mononucleotide) — Sinclair’s Signature Supplement

If there is a single supplement most closely associated with David Sinclair, it is NMN. He has discussed it in virtually every major interview, dedicated significant sections of Lifespan to the science of NAD+ precursors, and his Harvard lab has published multiple papers on NMN’s effects in animal models.

What Sinclair has said: On Joe Rogan Experience #1670 and in Lifespan, Sinclair explained that NAD+ levels decline with age, and that this decline is a key driver of the aging process. He has stated that he takes 1 gram of NMN every morning, mixed into yogurt. The yogurt serves a practical purpose — NMN is better absorbed with some fat content, and mixing it into food makes the somewhat bitter taste more palatable. Sinclair has described NMN as a precursor that the body converts into NAD+, which then activates sirtuins — a family of proteins his lab has spent decades studying that play key roles in DNA repair, gene expression regulation, and cellular stress response.

Reported dose: 1g (1,000mg) per day, taken in the morning with yogurt.

What the research shows: Sinclair’s lab at Harvard published a landmark 2013 study in Cell demonstrating that NMN supplementation restored NAD+ levels in aged mice and reversed several markers of aging in muscle tissue. A 2022 human clinical trial published in Science confirmed that oral NMN supplementation increases blood NAD+ levels in a dose-dependent manner. However — and this is where the controversy begins — no long-term randomized controlled trial has yet demonstrated that NMN supplementation meaningfully extends human lifespan or reverses aging-related diseases in humans. Most of the dramatic anti-aging findings have been in mice.

The FDA question: In late 2022, the FDA raised questions about whether NMN could be sold as a dietary supplement, given that it was being investigated as a drug by Metro International Biotech (a company Sinclair co-founded). This created significant market uncertainty. As of early 2026, NMN supplements remain widely available, though the regulatory landscape continues to evolve.

Conflict of interest note: Sinclair has co-founded or served as an advisor to companies with financial interests in NAD+ and sirtuin research, including Metro International Biotech and Life Biosciences. He has been transparent about these relationships, but readers should be aware of them when evaluating his advocacy for NMN.

Where to source NMN: Several third-party-tested NMN supplements are available. Look for products with certificates of analysis (COA) from independent labs. Check current pricing on Amazon

2. Resveratrol — Activating the Sirtuins

Resveratrol is the other pillar of Sinclair’s protocol, and possibly the most controversial. He has been publicly associated with resveratrol research since the mid-2000s, and his advocacy has continued despite a rocky history that includes the failure of a major pharmaceutical bet.

What Sinclair has said: In Lifespan and across dozens of interviews, Sinclair has stated that he takes 1 gram of resveratrol every morning, mixed into yogurt alongside his NMN. He describes resveratrol as an activator of SIRT1, the sirtuin he has studied most extensively. In his framing, NMN provides the fuel (NAD+) while resveratrol steps on the accelerator (activating sirtuins to use that fuel). He has compared it to needing both gasoline and a car — NAD+ is the gasoline, sirtuins are the engine, and resveratrol turns the ignition key.

Reported dose: 1g (1,000mg) per day, taken in the morning with yogurt (resveratrol is fat-soluble, and bioavailability increases significantly when taken with fat).

Research context: Sinclair’s early resveratrol research generated enormous excitement. His 2003 paper in Nature showed that resveratrol activated SIRT1 and extended lifespan in yeast. A 2006 Nature paper showed that resveratrol-fed mice on a high-fat diet lived longer and had better metabolic markers than control mice. But subsequent research muddied the picture considerably — see “The Resveratrol Controversy” section below for the full story.

Check current pricing on Amazon

3. Metformin — The Diabetes Drug for Longevity

Metformin is perhaps the most intriguing element of Sinclair’s protocol because it is a prescription pharmaceutical, not a supplement. Originally developed for type 2 diabetes, metformin has attracted enormous attention in the longevity community based on observational data suggesting that diabetic patients taking metformin sometimes outlive non-diabetic controls.

What Sinclair has said: Sinclair has stated in multiple interviews, including on JRE #1670 and in Lifespan, that he takes 850mg of metformin in the morning and 850mg in the evening (1,700mg total daily). He has described metformin as a caloric restriction mimetic that activates AMPK — an enzyme that triggers many of the same cellular pathways activated by fasting and exercise. Sinclair has noted that he does not take metformin on days when he exercises intensely, citing research suggesting metformin may blunt some exercise-induced adaptations, particularly mitochondrial biogenesis.

Reported dose: 850mg morning, 850mg evening (1,700mg total daily). Skips it on heavy exercise days.

The TAME trial: Sinclair has been a vocal supporter of the TAME trial (Targeting Aging with Metformin), a landmark NIH-funded clinical trial designed to test whether metformin can slow the onset of age-related diseases in non-diabetic older adults. The trial, led by Dr. Nir Barzilai at Albert Einstein College of Medicine, represents one of the first attempts to get the FDA to recognize aging as a treatable condition. Sinclair has argued that if TAME succeeds, it could fundamentally change how the medical establishment views aging — shifting it from an inevitable process to a condition that can be intervened upon.

Research context: A 2014 retrospective study in Diabetes, Obesity and Metabolism found that type 2 diabetics taking metformin had slightly longer survival than matched non-diabetic controls — a finding that generated headlines but also significant debate about confounding variables. A 2019 Cell Metabolism paper found that metformin attenuated some exercise benefits in older adults, which is why Sinclair and others skip it on exercise days.

Important: Metformin is a prescription medication with known side effects including gastrointestinal discomfort and potential B12 depletion. Sinclair takes it under medical supervision.

4. Vitamin D3 — Foundational Support

What Sinclair has said: Sinclair has mentioned vitamin D3 as part of his daily regimen in various interviews and social media posts, though he has discussed it with far less specificity than his core supplements. He has not publicly stated a specific dose, though his inclusion of D3 aligns with the broader consensus among longevity researchers that maintaining adequate vitamin D levels is foundational to health.

Research context: Vitamin D deficiency is common, and adequate levels are associated with immune function, bone health, and reduced risk of several age-related conditions. The Endocrine Society estimates that over 40% of American adults are deficient. While Sinclair has not made vitamin D a centerpiece of his public commentary, its inclusion in his protocol is consistent with virtually every other longevity expert we cover.

5. Omega-3 Fatty Acids — Anti-Inflammatory Foundation

What Sinclair has said: Sinclair has listed omega-3 fatty acids as part of his supplement routine in interviews and social media posts. Like vitamin D, he has not discussed omega-3s at the same length as NMN or resveratrol, but their inclusion reflects the broad expert consensus on their importance for cardiovascular health, brain health, and managing systemic inflammation.

Research context: Omega-3 supplementation has one of the strongest evidence bases of any supplement. Meta-analyses have consistently demonstrated cardiovascular benefits, and higher omega-3 intake is associated with reduced all-cause mortality in observational studies. For a deeper look at omega-3 supplementation across longevity experts, see our comparison of longevity expert stacks.

6. Quercetin — Senolytic and Anti-Inflammatory

What Sinclair has said: Sinclair has mentioned quercetin as part of his regimen in interviews and on social media. He has discussed it in the context of its senolytic properties — the ability to help clear senescent cells (sometimes called “zombie cells”) that accumulate with age and contribute to chronic inflammation and tissue dysfunction. Quercetin has also been studied as an anti-inflammatory and antioxidant.

Research context: A 2019 pilot study published in EBioMedicine (The Lancet’s partner journal) found that the combination of dasatinib and quercetin reduced senescent cell burden in patients with idiopathic pulmonary fibrosis. While quercetin alone is less potent than in combination with prescription senolytics, its availability as a supplement and favorable safety profile have made it popular in the longevity community. Sinclair has noted that senolytic approaches are one of several strategies he believes can slow or partially reverse aging.

7. Spermidine — Autophagy Activator

What Sinclair has said: Sinclair has discussed spermidine in conference talks and interviews as a supplement that promotes autophagy — the cellular self-cleaning process that degrades and recycles damaged components. He has included it in his publicly stated supplement list, describing it as part of his strategy to activate multiple longevity pathways simultaneously.

Research context: A 2018 study published in Science found that dietary spermidine intake was associated with reduced mortality in a population-based cohort study. Animal studies have shown that spermidine supplementation can extend lifespan in yeast, flies, worms, and mice. Human clinical trials are ongoing, with early results suggesting improvements in cognitive function and cardiovascular markers.

8. Fisetin — The Senolytic Flavonoid

What Sinclair has said: Sinclair has mentioned fisetin in the context of senolytic research. Found naturally in strawberries and other fruits, fisetin has gained attention in longevity circles for its ability to selectively clear senescent cells. Sinclair has discussed it as a supplement he takes periodically, though he has been less specific about his dosing regimen for fisetin compared to his core supplements.

Research context: A 2018 study published in EBioMedicine identified fisetin as the most potent senolytic among a panel of flavonoids tested. The study, conducted at the Mayo Clinic, showed that fisetin reduced senescent cell markers and extended lifespan in aged mice. However, human clinical data on fisetin remains limited, and optimal dosing protocols have not been established. Several clinical trials are underway.

Sinclair Is Why I Take NMN — And Why I Stopped Taking Resveratrol

Sinclair is the reason I take NMN. I’ll just say that upfront. His research on NAD+ decline with aging and the role of sirtuins in longevity is what put NMN on my radar in the first place. Without Sinclair, I probably wouldn’t be taking it.

But here’s where it gets complicated. I also took resveratrol because of Sinclair — and I stopped. The controversy around resveratrol, the questions about some of his research claims, and the broader scientific community’s pushback made me reevaluate. When other researchers started publicly questioning whether resveratrol’s benefits were overstated and whether Sinclair’s financial ties to supplement companies created conflicts of interest, I decided the risk-reward no longer made sense for resveratrol specifically.

I kept the NMN because the NAD+ research extends well beyond Sinclair’s lab. Multiple independent research groups have published on NAD+ decline with aging, and the human trials showing NMN raises NAD+ levels are real, even if the downstream health benefits are still being established. Sinclair put it on the map, but the science doesn’t depend on him being right about everything.

The lesson I took from the Sinclair experience: don’t build your protocol around any single expert. I made that mistake early — took resveratrol because Sinclair said to, not because I independently evaluated the evidence. Now I use a filter: does the research hold up if I remove the expert’s name from it? NMN passes that test. Resveratrol didn’t, at least not for me.

Sinclair is still worth following for the big-picture longevity framework. His work on epigenetic reprogramming and the information theory of aging is genuinely groundbreaking even if specific supplement recommendations have been controversial. Just approach his protocol with the same critical eye you’d apply to anyone selling something.

I track what every expert changes in their protocol and why. The CoreStacks Longevity Report — free, weekly.

The NMN Debate: Sinclair vs. the Skeptics

NMN is the supplement most closely associated with Sinclair, and it is also the one that generates the most heated debate among longevity researchers. Understanding the controversy is essential for anyone considering it.

Sinclair’s Position

Sinclair’s case for NMN rests on several pillars. First, NAD+ levels measurably decline with age — this is well-established in the research literature. Second, his lab’s animal research has demonstrated that restoring NAD+ levels via NMN supplementation can reverse multiple markers of aging in mice, including improvements in muscle function, blood vessel health, and endurance. Third, human trials have confirmed that oral NMN raises blood NAD+ levels. Sinclair has stated that he personally noticed improvements in energy and blood markers after starting NMN, though he acknowledges this is anecdotal.

His theoretical framework — the Information Theory of Aging — positions NAD+ decline as central to the aging process. In this model, NAD+ is required by sirtuins to maintain the epigenome (the molecular “instructions” that tell cells which genes to turn on and off). As NAD+ declines, sirtuins cannot function properly, the epigenome becomes noisy, cells lose their identity, and aging results. Restoring NAD+ with NMN is, in this framework, a way to give sirtuins the fuel they need to maintain epigenomic integrity.

The Skeptics’ Counterarguments

Dr. Brad Stanfield, the New Zealand physician and evidence-based longevity YouTuber, has produced multiple detailed video analyses questioning the NMN evidence base. Stanfield’s primary criticisms include: the lack of long-term human RCT data demonstrating that NMN extends healthspan or lifespan in humans; the gap between dramatic mouse results and the modest human data available; and the concern that Sinclair’s financial conflicts of interest (as co-founder of companies in the NAD+ space) complicate his role as an impartial scientific advocate. Stanfield has stated on his YouTube channel that he does not take NMN himself, favoring supplements with stronger human evidence. For more on Stanfield’s approach, see our Brad Stanfield supplement protocol guide.

Dr. Peter Attia, host of The Drive podcast and author of Outlive, has expressed a more measured skepticism. Attia has acknowledged the theoretical rationale for NAD+ precursors but has stated on multiple podcast episodes that he does not consider the current human evidence sufficient to justify confident recommendations. Attia has noted that he has experimented with both NMN and NR (nicotinamide riboside) but has not made either a consistent part of his protocol, preferring to wait for more definitive human trial data. For a full comparison of NMN vs. NR and what different experts recommend, see our NMN vs. NR guide.

Where the Evidence Currently Stands

As of early 2026, the honest summary is: NMN raises NAD+ levels in humans (confirmed), NMN has dramatic anti-aging effects in mice (confirmed), and no human trial has yet demonstrated that taking NMN meaningfully extends lifespan or reverses aging-related disease in humans (also accurate). Sinclair would argue that the animal data is compelling enough to justify personal use while waiting for human data. The skeptics would argue that the history of medicine is littered with interventions that worked brilliantly in mice and failed in humans. Both sides have legitimate points.

The Resveratrol Controversy

The resveratrol story is one of the most dramatic narratives in modern longevity science, and understanding it is critical context for anyone evaluating Sinclair’s protocol.

The Rise

Sinclair’s early research on resveratrol generated global headlines. His 2003 Nature paper showed that resveratrol activated SIRT1 and extended lifespan in yeast. A 2006 Nature paper demonstrated that resveratrol dramatically improved health outcomes in mice fed a high-fat diet. The media dubbed resveratrol the “red wine molecule” (it is found in grape skins), and supplement sales skyrocketed. Sinclair co-founded Sirtris Pharmaceuticals to develop resveratrol-based drugs, and in 2008, GlaxoSmithKline acquired Sirtris for $720 million.

The Fall

Things unraveled. In 2010, GlaxoSmithKline halted development of SRT501 (a proprietary resveratrol formulation) after a clinical trial in multiple myeloma patients showed potential safety concerns, including kidney damage in some participants. Subsequent research by other labs questioned whether resveratrol was truly a direct SIRT1 activator or whether the original assay results were artifacts of the fluorescent tag used in the experiment. A 2013 paper in The Journal of Biological Chemistry by a team at Amgen argued that resveratrol’s effects on SIRT1 in the original studies were assay artifacts. GSK eventually shut down the Sirtris operation entirely.

Sinclair’s Continued Advocacy

Despite this history, Sinclair has continued to take resveratrol and advocate for it. He has addressed the controversy directly, arguing on JRE and in interviews that: (1) the GSK failure was of a specific pharmaceutical formulation at specific doses, not of resveratrol itself; (2) subsequent research from his lab and others has confirmed that resveratrol does activate SIRT1 through a mechanism involving specific substrates; and (3) his personal experience and blood markers support continued use. A 2013 Science paper from his lab presented evidence that resveratrol does directly activate SIRT1, but through a mechanism that was not captured by the original assay — attempting to settle the debate.

The Current State of Evidence

The resveratrol evidence base remains genuinely mixed. Animal studies continue to show benefits. Some human trials have shown improvements in vascular function and metabolic markers. But there is no human RCT demonstrating that resveratrol extends lifespan, and the GSK/Sirtris episode has cast a long shadow over the field. Sinclair’s continued advocacy, combined with his financial history with Sirtris, is a point of legitimate criticism that readers should weigh when evaluating his recommendations.

Sinclair’s Information Theory of Aging

Understanding why Sinclair takes what he takes requires understanding his theory of why we age. Most longevity researchers would agree that aging involves the accumulation of damage — DNA mutations, protein misfolding, mitochondrial dysfunction, cellular senescence. Sinclair agrees that all of these happen, but he argues that they are symptoms, not the root cause.

In Sinclair’s Information Theory of Aging, laid out in Lifespan, the primary driver of aging is the loss of epigenetic information. Every cell in the body contains the same DNA, but different cells read different parts of it. The epigenome — a layer of chemical markers and protein structures that sits on top of DNA — determines which genes are active in which cells. A liver cell “knows” it is a liver cell because its epigenome tells it which genes to read.

Sinclair argues that as we age, this epigenomic information degrades. DNA damage forces sirtuins (which normally maintain the epigenome) to abandon their posts to help with DNA repair. Over time, the epigenome becomes noisy, cells begin to lose their identity, and the downstream consequences manifest as the diseases and decline we associate with aging. In this framework, aging is fundamentally an information problem — and one that might be reversible if we can restore the epigenomic information.

This theory drives Sinclair’s supplement choices: NMN to fuel the sirtuins (via NAD+), resveratrol to activate them, and metformin to activate complementary pathways (AMPK). It also drives his lab’s more speculative research into Yamanaka factors — a set of proteins that can reprogram adult cells back to a stem-cell-like state, effectively resetting the epigenome. Sinclair’s lab has published research in Nature demonstrating that partial reprogramming with Yamanaka factors can restore vision in aged mice, suggesting that epigenomic information is not permanently lost but can be recovered.

What’s Changed Recently in Sinclair’s Protocol

Sinclair has been relatively consistent with his core protocol over the years, but there have been notable shifts and updates:

2023-2024: NMN Regulatory Uncertainty

The FDA’s questioning of NMN’s supplement status created uncertainty in the market. Sinclair addressed this publicly, expressing concern about potential regulatory restrictions on a compound he considers essential to his protocol. As of early 2026, NMN supplements remain available, though the regulatory situation is worth monitoring.

2023-2024: Increased Discussion of Senolytics

In interviews and conference appearances, Sinclair has increasingly discussed senolytic compounds (quercetin, fisetin) as part of a multi-pathway approach to aging. This represents a broadening of his public protocol beyond the NMN-resveratrol-metformin core.

2024: Yamanaka Factor Research Progress

Sinclair’s lab continued publishing on partial cellular reprogramming using Yamanaka factors, with results in mouse models showing restored tissue function. While not a supplement protocol change, this research direction signals where Sinclair sees the future of longevity intervention heading — and it reinforces his Information Theory framework.

2024-2025: More Emphasis on Lifestyle Factors

In more recent interviews, Sinclair has placed greater emphasis on the lifestyle components of his protocol — intermittent fasting, exercise, cold exposure, and stress management — alongside the supplement regimen. He has noted that supplements alone are insufficient without these foundational behaviors.

Ongoing: Conflict-of-Interest Transparency

Sinclair has continued to be publicly transparent about his financial relationships with NAD+ and sirtuin-focused companies, though critics argue that transparency alone does not resolve the conflict. This remains a live issue in evaluating his recommendations.

How Sinclair’s Approach Compares to Other Longevity Experts

One of the most useful things we can do is place Sinclair’s protocol in context alongside the other longevity researchers we cover. The differences are revealing.

Sinclair vs. Peter Attia

Attia and Sinclair agree on the importance of exercise, metabolic health, and addressing aging proactively. But their supplement approaches diverge significantly. Attia takes a notably more conservative approach to supplementation, focusing heavily on foundational compounds with strong human evidence (omega-3s, vitamin D, magnesium) and relying more on prescription medications backed by clinical trials (like PCSK9 inhibitors and GLP-1 agonists for specific indications). Attia has expressed skepticism about NMN’s current evidence base and notably stopped taking metformin after reviewing the evidence on its interference with exercise adaptations. Sinclair still takes metformin (skipping it on exercise days). For a full breakdown, see our comparison of longevity expert stacks.

Sinclair vs. Brad Stanfield

The contrast here is starker. Stanfield is perhaps the most evidence-conservative longevity influencer we cover, insisting on high-quality human RCT data before recommending any supplement. Stanfield has publicly critiqued NMN and resveratrol as having insufficient human evidence, and he has flagged Sinclair’s financial conflicts of interest as a concern. Stanfield’s personal stack is notably smaller and cheaper than Sinclair’s, favoring compounds like creatine, vitamin D, and omega-3s that have deep human evidence bases. See our Brad Stanfield supplement protocol guide for the full comparison.

Sinclair vs. Andrew Huberman

Huberman occupies a middle ground. He takes NMN (influenced in part by his conversations with Sinclair on the Huberman Lab podcast) but his broader stack is oriented more toward cognitive performance and hormonal optimization than pure longevity. Huberman has been generally supportive of the NAD+ thesis while being more cautious in his language than Sinclair. Notably, Huberman does not take resveratrol or metformin as part of his publicly stated protocol. See our Huberman supplement stack guide for details.

The Common Ground

Despite their differences, there are areas where Sinclair, Attia, Stanfield, and Huberman largely agree: the importance of exercise (especially resistance training and zone 2 cardio), adequate sleep, omega-3 supplementation, vitamin D sufficiency, and the potential value of intermittent fasting or time-restricted eating. See our what longevity experts agree and disagree on for a comprehensive analysis.

Get the latest longevity research in your inbox every week.

Join Free →

Research Disclaimer

Research Context: The supplements and protocols discussed in this article reflect Dr. David Sinclair’s publicly shared views and are reported here for informational purposes only. Individual responses to supplements and medications vary significantly based on genetics, health status, and other factors. Metformin is a prescription medication that should only be taken under medical supervision. Always consult with a qualified healthcare professional before making changes to your supplement or pharmaceutical regimen.

Financial Disclosure Context: As noted throughout this article, Dr. Sinclair has co-founded and advised companies with financial interests in NAD+ and sirtuin research. CoreStacks reports this for transparency and encourages readers to weigh these relationships when evaluating his public recommendations.

FAQ

Does David Sinclair still take NMN in 2026?

Based on Sinclair’s most recent public statements (interviews and social media activity through late 2025), he continues to take NMN as a core part of his daily protocol. He has been taking it consistently since at least the publication of Lifespan in 2019 and has shown no indication of stopping. His reported dose remains 1g per day, taken in the morning with yogurt.

Does Sinclair still take resveratrol despite the controversy?

Yes. Despite the GSK/Sirtris failure and ongoing scientific debate about resveratrol’s mechanism, Sinclair has continued to take 1g of resveratrol daily. He has addressed the controversy directly in multiple interviews, arguing that the pharmaceutical failure was specific to a particular formulation and does not invalidate resveratrol’s benefits when taken as a supplement alongside NMN.

How much does David Sinclair’s supplement protocol cost per month?

The cost varies significantly depending on brands and sourcing, but a rough estimate for the supplement components (NMN 1g, resveratrol 1g, quercetin, spermidine, fisetin, vitamin D3, omega-3) runs approximately $200-$400 per month. NMN is the most expensive component, typically costing $50-$150/month for quality third-party-tested products at 1g/day. Metformin is relatively inexpensive as a generic prescription ($10-$30/month) but requires a doctor’s prescription and monitoring.

Why does Sinclair mix supplements with yogurt?

Sinclair has explained that both NMN and resveratrol are better absorbed when taken with fat. Resveratrol in particular is fat-soluble and has significantly better bioavailability when consumed with a fat source. Yogurt provides this fat while also making the supplements (especially resveratrol, which can be bitter) more palatable. He has stated that he specifically uses full-fat yogurt in the morning for this purpose.

Is it safe to take metformin without diabetes?

Metformin is FDA-approved for type 2 diabetes and is used off-label by some physicians for longevity purposes. It has a well-established safety profile in diabetic populations, with common side effects including gastrointestinal discomfort (especially when starting) and potential vitamin B12 depletion over time. However, the TAME trial is specifically designed to test metformin’s safety and efficacy for non-diabetic longevity purposes, and results are not yet available. Sinclair has emphasized that he takes metformin under medical supervision. Anyone considering metformin for longevity should discuss it with their physician — this is a prescription medication, not a supplement.

What is the TAME trial and when will results be available?

The TAME trial (Targeting Aging with Metformin) is an NIH-funded, multi-center clinical trial led by Dr. Nir Barzilai at Albert Einstein College of Medicine. It aims to test whether metformin can delay the onset of age-related diseases (cancer, cardiovascular disease, dementia) in non-diabetic adults aged 65-79. The trial is significant beyond its specific findings because it represents one of the first attempts to get the FDA to recognize aging itself as a targetable condition. Sinclair has been a vocal advocate for the trial. Enrollment and dosing timelines have shifted over the years, and as of early 2026, final results have not yet been published.

Why do some experts disagree with Sinclair about NMN?

The disagreement centers on evidence standards. Sinclair points to strong animal data, confirmed NAD+ increases in humans, and a compelling theoretical framework. Critics like Stanfield and Attia counter that (1) no human RCT has shown NMN extends healthspan or lifespan, (2) many interventions that work in mice fail in humans, (3) Sinclair’s financial ties to NAD+ companies complicate his objectivity, and (4) the cost-benefit ratio of NMN (expensive, uncertain human benefit) compares unfavorably to cheaper interventions with stronger human evidence (exercise, omega-3s, vitamin D). Both sides have valid points, and the debate will likely continue until long-term human trial data is available.

What are Yamanaka factors and why is Sinclair researching them?

Yamanaka factors are a set of four proteins (Oct4, Sox2, Klf4, and c-Myc, collectively known as OSKM) that can reprogram adult cells back to a pluripotent stem cell state. Discovered by Shinya Yamanaka (who won the 2012 Nobel Prize for this work), they have become central to Sinclair’s vision of the future of aging intervention. Sinclair’s lab has published research demonstrating that partial expression of three of these factors (OSK, excluding c-Myc due to cancer risk) can reverse aging markers in mouse tissues — notably restoring vision in aged mice — without fully reprogramming cells to a stem-cell state. Sinclair argues that this supports his Information Theory of Aging: the youthful epigenomic information is still stored somewhere in the cell and can be recovered. This is a research direction, not a supplement, and human applications are still years or decades away.

Keep Reading

Sources

Books

  • Sinclair, D.A. with LaPlante, M.D., Lifespan: Why We Age — and Why We Don’t Have To, Atria Books, 2019

Podcast Appearances

  • Joe Rogan Experience #1670 — David Sinclair, aired 2021 (primary protocol discussion)
  • Joe Rogan Experience #1349 — David Sinclair, aired 2019 (early protocol discussion)
  • The Drive with Peter Attia — multiple episodes discussing NAD+ biology and longevity interventions
  • Huberman Lab — episodes featuring Sinclair discussing NMN, NAD+, and sirtuins

Published Research

  • Gomes, A.P., Price, N.L., Ling, A.J.Y., et al., “Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging,” Cell, 2013 — PMID: 24360282
  • Baur, J.A., Pearson, K.J., Price, N.L., et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” Nature, 2006 — PMID: 17086191
  • Howitz, K.T., Bitterman, K.J., Cohen, H.Y., et al., “Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan,” Nature, 2003 — PMID: 12939617
  • Hubbard, B.P., Gomes, A.P., Dai, H., et al., “Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators,” Science, 2013 — PMID: 23483735
  • Lu, Y., Brommer, B., Tian, X., et al., “Reprogramming to recover youthful epigenetic information and restore vision,” Nature, 2020 — PMID: 33268865
  • Bannister, C.A., Holden, S.E., Jenkins-Jones, S., et al., “Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls,” Diabetes, Obesity and Metabolism, 2014 — PMID: 24988509
  • Konopka, A.R., Laurin, J.L., Schoenberg, H.M., et al., “Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults,” Aging Cell, 2019 — PMID: 30548390
  • Yousefzadeh, M.J., Zhu, Y., McGowan, S.J., et al., “Fisetin is a senotherapeutic that extends health and lifespan,” EBioMedicine, 2018 — PMID: 30279143
  • Eisenberg, T., Abdellatif, M., Schroeder, S., et al., “Cardioprotection and lifespan extension by the natural polyamine spermidine,” Nature Medicine, 2016 — PMID: 27841876

Critical Analyses

  • Pacholec, M., Bleasdale, J.E., Chrunyk, B., et al., “SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1,” The Journal of Biological Chemistry, 2010 — PMID: 20061378
  • Stanfield, B., multiple YouTube analyses of NMN evidence base, 2023-2025
  • TAME Trial information: American Federation for Aging Research (AFAR), afar.org

If you made it this far, you'll like the newsletter. One email per week — the research that matters, the supplements that work, the ones that don't. Free.

Join the Newsletter →

Share Article

Author

Mike Hartnett

Mike tracks what leading longevity researchers actually take, test, and recommend. CoreStacks reports on expert protocols and published research to help you make informed decisions about your health.

Follow Me
Other Articles

Related Posts

Scroll

Our site uses cookies. By using this site, you agree to the Privacy Policy

Accept